Liesa K Hoppe1,2, Dana C Muhlack1,2, Wolfgang Koenig3,4,5, Prudence R Carr2, Hermann Brenner1,2, Ben Schöttker6,7,8. 1. Network Aging Research, University of Heidelberg, Heidelberg, Germany. 2. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. 3. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. 4. DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Technische Universität München, Munich, Germany. 5. Department of Internal Medicine II - Cardiology, University of Ulm Medical Centre, Ulm, Germany. 6. Network Aging Research, University of Heidelberg, Heidelberg, Germany. b.schoettker@dkfz-heidelberg.de. 7. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. b.schoettker@dkfz-heidelberg.de. 8. Institute of Health Care and Social Sciences, FOM University, Essen, Germany. b.schoettker@dkfz-heidelberg.de.
Abstract
PURPOSE: To provide the first systematic review and meta-analysis of observational studies on the association of abnormal serum potassium and cardiovascular outcomes. METHODS: Medline and ISI Web of Knowledge were systematically searched from inception until November 24, 2017. Data synthesis of relevant studies was performed using random effects model meta-analyses. RESULTS: Meta-analyses included 310,825 participants from 24 studies. In the older general population, low serum potassium was associated with a 1.6-fold increased risk of supraventricular arrhythmias (risk ratio [95% confidence interval] 1.62 [1.02-2.55]). Contrarily, high serum potassium was associated with increased cardiovascular mortality (CVM) (1.38 [1.14-1.66]). In patients with acute myocardial infarction, the risk of ventricular arrhythmias was increased for high serum potassium (2.33 [1.60-3.38]). A U-shaped association was observed with a composite cardiovascular outcome in hypertensive patients (2.6-fold increased risk with hypokalemia and 1.7-fold increased risk with hyperkalemia), with CVM in dialysis patients (1.1-fold increased risk with hypokalemia and 1.4-fold increased risk with hyperkalemia) and with CVM in heart failure patients (albeit not statistically significant). Further, only hyperkalemia was associated with an increased risk of a composite cardiovascular outcome in both dialysis (1.12 [1.03-1.23]) and chronic kidney disease (1.34 [1.06-1.71]) patients. CONCLUSIONS: Controlled clinical trials are needed to determine which populations may profit from more frequent potassium-monitoring and subsequent interventions, e.g., change or withdrawal of potassium-influencing drugs, in order to restore normal values and prevent cardiovascular outcomes. REGISTRATION DETAILS: Registration in PROSPERO (Centre for Reviews and Dissemination University of York, York, UK): CRD42016048897 ( https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=48897 ).
PURPOSE: To provide the first systematic review and meta-analysis of observational studies on the association of abnormal serum potassium and cardiovascular outcomes. METHODS: Medline and ISI Web of Knowledge were systematically searched from inception until November 24, 2017. Data synthesis of relevant studies was performed using random effects model meta-analyses. RESULTS: Meta-analyses included 310,825 participants from 24 studies. In the older general population, low serum potassium was associated with a 1.6-fold increased risk of supraventricular arrhythmias (risk ratio [95% confidence interval] 1.62 [1.02-2.55]). Contrarily, high serum potassium was associated with increased cardiovascular mortality (CVM) (1.38 [1.14-1.66]). In patients with acute myocardial infarction, the risk of ventricular arrhythmias was increased for high serum potassium (2.33 [1.60-3.38]). A U-shaped association was observed with a composite cardiovascular outcome in hypertensivepatients (2.6-fold increased risk with hypokalemia and 1.7-fold increased risk with hyperkalemia), with CVM in dialysis patients (1.1-fold increased risk with hypokalemia and 1.4-fold increased risk with hyperkalemia) and with CVM in heart failurepatients (albeit not statistically significant). Further, only hyperkalemia was associated with an increased risk of a composite cardiovascular outcome in both dialysis (1.12 [1.03-1.23]) and chronic kidney disease (1.34 [1.06-1.71]) patients. CONCLUSIONS: Controlled clinical trials are needed to determine which populations may profit from more frequent potassium-monitoring and subsequent interventions, e.g., change or withdrawal of potassium-influencing drugs, in order to restore normal values and prevent cardiovascular outcomes. REGISTRATION DETAILS: Registration in PROSPERO (Centre for Reviews and Dissemination University of York, York, UK): CRD42016048897 ( https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=48897 ).
Authors: Kevin F O'Sullivan; Mohammad Amin Kashef; Alexander B Knee; Alexander S Roseman; Penelope S Pekow; Mihaela S Stefan; Meng-Shiou Shieh; Quinn R Pack; Peter K Lindenauer; Tara Lagu Journal: J Hosp Med Date: 2019-07-24 Impact factor: 2.960
Authors: Precil Diego Miranda de Menezes Neves; Ricardo de Castro Cintra Sesso; Fernando Saldanha Thomé; Jocemir Ronaldo Lugon; Marcelo Mazza Nascimento Journal: J Bras Nefrol Date: 2021 Apr-Jun
Authors: Mia Ravn Jacobsen; Reza Jabbari; Charlotte Glinge; Niels Kjær Stampe; Jawad Haider Butt; Paul Blanche; Jacob Lønborg; Olav Wendelboe Nielsen; Lars Køber; Christian Torp-Pedersen; Frants Pedersen; Jacob Tfelt-Hansen; Thomas Engstrøm Journal: J Am Heart Assoc Date: 2020-02-12 Impact factor: 5.501
Authors: Charat Thongprayoon; Wisit Cheungpasitporn; Panupong Hansrivijit; Michael A Mao; Juan Medaura; Tarun Bathini; Api Chewcharat; Stephen B Erickson Journal: Medicines (Basel) Date: 2019-12-30